Tissue and Plasma Angiotensin Converting Enzyme and the Response to ACE Inhibitor Drugs

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1991 Jan 1

PMID 1849731

Citations 8

Authors

R J MacFadyen

K R Lees

J L Reid

Affiliations

Soon will be listed here.

Abstract

1. There is a body of circumstantial and direct evidence supporting the existence and functional importance of a tissue based RAS at a variety of sites. 2. The relation between circulatory and tissue based systems is complex. The relative importance of the two in determining haemodynamic effects is unknown. 3. Despite the wide range of ACE inhibitors already available, it remains unclear whether there are genuine differences related to tissue specificity. 4. Pathological states such as chronic cardiac failure need to be explored with regard to the contribution of tissue based ACE activities in generating acute and chronic haemodynamic responses to ACE inhibitors. 5. The role of tissue vs plasma ACE activity may be clarified by study of the relation between drug concentration and haemodynamic effect, provided that the temporal dissociation is examined and linked to circulating and tissue based changes in ACE activity, angiotensin peptides and sympathetic hormones.

Citing Articles

Chiropractic care for hypertension: Review of the literature and study of biological and genetic bases.

Sullivan S, Paolacci S, Kiani A, Bertelli M Acta Biomed. 2020; 91(13-S):e2020017.

PMID: 33170172 PMC: 8023135. DOI: 10.23750/abm.v91i13-S.10524.

Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria.

Andersen N, Mogensen C Curr Hypertens Rep. 2002; 4(5):394-402.

PMID: 12217259 DOI: 10.1007/s11906-002-0070-x.

Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity.

Kimura M, Umemura K, Kosuge K, Nishimoto M, Ohashi K, Nakashima M Br J Clin Pharmacol. 1998; 46(6):599-603.

PMID: 9862250 PMC: 1873805. DOI: 10.1046/j.1365-2125.1998.00834.x.

Haemodynamic and hormonal responses to oral enalapril in salt depleted normotensive man.

MacFadyen R, Elliott H, MEREDITH P, Reid J Br J Clin Pharmacol. 1993; 35(3):299-301.

PMID: 8471406 PMC: 1381578. DOI: 10.1111/j.1365-2125.1993.tb05697.x.

Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure.

MacFadyen R, Lees K, Reid J Br Heart J. 1993; 69(4):293-7.

PMID: 8387806 PMC: 1025039. DOI: 10.1136/hrt.69.4.293.

References

Linehan J, Bronikowski T, Rickaby D, Dawson C . Hydrolysis of a synthetic angiotensin-converting enzyme substrate in dog lungs. Am J Physiol. 1989; 257(6 Pt 2):H2006-16. DOI: 10.1152/ajpheart.1989.257.6.H2006. View

SCHALEKAMP M, Admiraal P, Derkx F . Estimation of regional metabolism and production of angiotensins in hypertensive subjects. Br J Clin Pharmacol. 1989; 28 Suppl 2:105S-112S; discussion 112S-113S. PMC: 1379849. DOI: 10.1111/j.1365-2125.1989.tb03586.x. View

Burnier M, Waeber B, Nussberger J, Brunner H . Pharmacokinetics of angiotensin converting enzyme inhibitors. Br J Clin Pharmacol. 1989; 28 Suppl 2:133S-139S; discussion 140S. PMC: 1379853. DOI: 10.1111/j.1365-2125.1989.tb03588.x. View

Admiraal P, Derkx F, Danser A, Pieterman H, SCHALEKAMP M . Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension. 1990; 15(1):44-55. DOI: 10.1161/01.hyp.15.1.44. View

Chai S, McKenzie J, McKinley M, Mendelsohn F . Angiotensin converting enzyme in the human basal forebrain and midbrain visualized by in vitro autoradiography. J Comp Neurol. 1990; 291(2):179-94. DOI: 10.1002/cne.902910203. View

Raij L, Shultz P, Tolins J . Possible mechanism for the renoprotective effect of angiotensin converting enzyme inhibitors. J Hypertens Suppl. 1989; 7(7):S33-6; discussion S36-7. DOI: 10.1097/00004872-198909007-00007. View

Lees K, Kelman A, Reid J, Whiting B . Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding. J Pharmacokinet Biopharm. 1989; 17(5):529-50. DOI: 10.1007/BF01071348. View

Johnston C, Cubela R, Jackson B . Relative inhibitory potency and plasma drug levels of angiotensin converting enzyme inhibitors in the rat. Clin Exp Pharmacol Physiol. 1988; 15(2):123-9. DOI: 10.1111/j.1440-1681.1988.tb01053.x. View

Gasic S, Dudczak R, Korn A, Kleinbloesem C . ACE inhibition with cilazapril improves myocardial perfusion to the ischemic regions during exercise: a pilot study. J Cardiovasc Pharmacol. 1990; 15(2):227-32. DOI: 10.1097/00005344-199002000-00008. View

10.

Kiowski W, van Brummelen P, Hulthen L, Amann F, Buhler F . Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation. Clin Pharmacol Ther. 1982; 31(6):677-84. DOI: 10.1038/clpt.1982.95. View

11.

Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P . Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987; 57(1):17-22. PMC: 1277140. DOI: 10.1136/hrt.57.1.17. View

12.

Sakharov I, Danilov S, Dukhanina E . Affinity chromatography and some properties of the angiotensin-converting enzyme from human heart. Biochim Biophys Acta. 1987; 923(1):143-9. DOI: 10.1016/0304-4165(87)90137-1. View

13.

Hornung R, Hillis W . The acute haemodynamic effects of intravenous enalaprilic acid (MK422) in patients with left ventricular dysfunction. Br J Clin Pharmacol. 1987; 23(1):29-33. PMC: 1386136. DOI: 10.1111/j.1365-2125.1987.tb03005.x. View

14.

Francis R, Brown A, Kler L, Fasanella dAmore T, Nussberger J, Waeber B . Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol. 1987; 9(1):32-8. View

15.

Packer M, Gottlieb S, BLUM M . Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with congestive heart failure. Am J Med. 1987; 82(3A):4-10. DOI: 10.1016/0002-9343(87)90126-4. View

16.

Neilly J, CLARK C, Tweddel A, Rae A, Hughes D, Hutton I . Transpulmonary angiotensin II formation in patients with chronic stable cor pulmonale. Am Rev Respir Dis. 1987; 135(4):891-5. DOI: 10.1164/arrd.1987.135.4.891. View

17.

De Marco T, Daly P, Liu M, Kayser S, Parmley W, Chatterjee K . Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure. J Am Coll Cardiol. 1987; 9(5):1131-8. DOI: 10.1016/s0735-1097(87)80318-2. View

18.

Marchetti J, Roseau S, Alhenc-Gelas F . Angiotensin I converting enzyme and kinin-hydrolyzing enzymes along the rabbit nephron. Kidney Int. 1987; 31(3):744-51. DOI: 10.1038/ki.1987.61. View

19.

Ajayi A, Hockings N, Reid J . The relationship between serum enalaprilat concentration and the hypotensive effect in man. Int J Clin Pharmacol Res. 1987; 7(1):1-3. View

20.

Marre M, Leblanc H, Suarez L, Guyenne T, Menard J, Passa P . Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J (Clin Res Ed). 1987; 294(6585):1448-52. PMC: 1246608. DOI: 10.1136/bmj.294.6585.1448. View